Hypothesis: daptomycin permeabilizes membranes by forming self assembled nanotubes
Daptomycin is the only lipopeptide antibiotic that is widely used in clinical practice. It was discovered by Eli Lilly and then studied and commercialized by Cubist Pharmaceuticals in 2003. Although this antibiotic has been used for 17 years, the debate over its mechanism of action is ongoing. In th...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Doctrine
2020-11-01
|
| Series: | Microbiology Independent Research Journal |
| Online Access: | https://www.scienceopen.com/hosted-document?doi=10.18527/2500-2236-2020-7-1-59-71 |